RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Peritoneal infusion of heated chemotherapy drugs, such as mitomycin, may kill more tumor cells. PURPOSE: This phase II trial is studying how well mitomycin works when given as a hyperthermic peritoneal perfusion in treating patients with malignant ascites.
OBJECTIVES: Primary * Determine the effectiveness of laparoscopic hyperthermic perfusion of mitomycin C in preventing relapse at 4 weeks post-treatment in patients with malignant ascites. Secondary * Determine any improvement in the quality of life of patients treated with this procedure. OUTLINE: This is a nonrandomized study. Patients undergo laparoscopic surgery to remove ascitic fluid and any intraabdominal adhesions and to place 2 inflow and 2 outflow catheters. Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes. Quality of life is assessed at study entry and at 4 weeks. After completion of study treatment, patients are followed periodically for 2 years.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1
Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
Prevention of malignant recurrence
Time frame: Week 4 after treatment
Quality of life after treatment
Time frame: Week 4 after treatment
Comparison of serum vascular endothelial growth factor (VEGF) levels
Time frame: Pretreatment and Week 4 after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.